Nasdaq:REPL

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 07, 2025 16:01 ET  | Source: Replimune Group Inc WOBURN, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group,…

2 months ago
Replimune Announces Inducement Grants Under NasdaqListing Rule 5635(c)(4)Replimune Announces Inducement Grants Under NasdaqListing Rule 5635(c)(4)

Replimune Announces Inducement Grants Under NasdaqListing Rule 5635(c)(4)

February 07, 2025 16:01 ET  | Source: Replimune Group Inc WOBURN, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group,…

3 months ago
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

November 09, 2024 13:00 ET | Source: Replimune Group Inc Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity…

6 months ago